Editas Medicine, Inc. Announces Auditor Change from Ernst & Young to PwC

Key Points

• Editas Medicine, Inc. (NASDAQ: EDIT) has dismissed Ernst & Young LLP as its independent registered public accounting firm, effective immediately.
• PricewaterhouseCoopers LLP (PwC) has been appointed as the new independent auditor for the fiscal year ending December 31, 2026.
• The change was made after a formal review and proposal process conducted by the Audit Committee of the Board of Directors.
• There were no disagreements or “reportable events” between Editas and Ernst & Young on any accounting or audit matters for fiscal years 2024, 2025, or the interim period through April 1, 2026.
• The company’s previous audit opinions from Ernst & Young for 2024 and 2025 were unqualified and not modified in any respect.
• Ernst & Young has provided a letter to the SEC confirming its agreement with the company’s disclosures regarding the change.

Details Investors Should Know

Editas Medicine, Inc. has announced a significant change in its corporate governance by replacing its independent registered public accounting firm. On April 1, 2026, the Audit Committee of the Board of Directors decided to dismiss Ernst & Young LLP and to appoint PricewaterhouseCoopers LLP (PwC) as the company’s new auditor, effective immediately, for the fiscal year ending December 31, 2026.

Background and Rationale

The decision followed a thorough and formal review process, including the solicitation of proposals from several accounting firms. This action comes as part of the company’s ongoing efforts to ensure best practices in financial reporting and oversight. The company formally notified Ernst & Young of its decision on April 2, 2026.

No Disagreements or Negative Audit Opinions

• Ernst & Young’s audit reports for the years ended December 31, 2024, and December 31, 2025, did not contain any adverse opinions, disclaimers, or modifications related to uncertainty, audit scope, or accounting principles.
• There were no disagreements (as defined in SEC regulations) between Editas and Ernst & Young regarding accounting principles, financial statement disclosures, or audit procedures.
• There were no reportable events during the fiscal years 2024 and 2025, or the interim period through April 1, 2026.

Confirmation Letter from Ernst & Young

Consistent with SEC requirements, Editas provided Ernst & Young with a copy of its disclosure regarding the auditor change. In response, Ernst & Young has issued a letter to the SEC affirming its agreement with the company’s statements about the nature of its departure and confirming the absence of any unresolved disagreements or reportable events.

Appointment of PwC as New Auditor

As of April 1, 2026, PwC has been appointed as the new independent registered public accounting firm. Notably, neither Editas nor anyone acting on its behalf has previously consulted with PwC on accounting principles, auditing matters, or any issues that would constitute a disagreement or reportable event as defined under SEC regulations.

Potential Impact on Shareholders and Share Price

Why This Matters: A change in independent auditors can be a material event for shareholders, as it may signal shifts in corporate governance, financial strategy, or internal controls. However, the lack of disagreements, adverse opinions, or reportable events in this case suggests the transition is part of normal corporate oversight rather than a reaction to financial reporting concerns.

Investors should monitor future filings and communications from Editas Medicine, Inc. for any further details regarding the transition to PwC and the results of future audits under the new firm.

Company Profile:

Editas Medicine, Inc. is a biotechnology company focused on developing transformative genome editing therapies.

Address: 11 Hurley St., Cambridge, MA 02141

Trading Symbol: EDIT (NASDAQ)

Exhibit Reference

The company has filed as Exhibit 16.1 the letter from Ernst & Young to the SEC, dated April 7, 2026, confirming the details above.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with their financial advisors before making any investment decisions. The author and publisher are not responsible for any losses that may result from reliance on this information.

View Editas Medicine, Inc. Historical chart here